Cargando…

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

OBJECTIVES: To evaluate clinical remission with subcutaneous abatacept plus methotrexate (MTX) and abatacept monotherapy at 12 months in patients with early rheumatoid arthritis (RA), and maintenance of remission following the rapid withdrawal of all RA treatment. METHODS: In the Assessing Very Earl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emery, Paul, Burmester, Gerd R, Bykerk, Vivian P, Combe, Bernard G, Furst, Daniel E, Barré, Emilie, Karyekar, Chetan S, Wong, Dennis A, Huizinga, Tom W J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283672/ https://www.ncbi.nlm.nih.gov/pubmed/25367713 http://dx.doi.org/10.1136/annrheumdis-2014-206106

Ejemplares similares

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study
por: Emery, Paul, et al.
Publicado: (2019)

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
por: Peterfy, Charles, et al.
Publicado: (2016)

The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study
por: Emery, Paul, et al.
Publicado: (2023)

Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
por: Emery, Paul, et al.
Publicado: (2023)

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
por: Schiff, M, et al.
Publicado: (2009)

Frailty and driving status associated with disability: a 24-month follow-up longitudinal study
por: Doi, Takehiko, et al.
Publicado: (2021)

Effect of obesity on functional outcomes at 6 months post-stroke among elderly Koreans: a prospective multicentre study
por: Jang, Shin Yi, et al.
Publicado: (2015)

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis
por: Westhovens, Rene, et al.
Publicado: (2015)

Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria
por: Iking-Konert, Christof, et al.
Publicado: (2011)

Impact of selected risk factors on motor performance in the third month of life and motor development in the ninth month
por: Gajewska, Ewa, et al.
Publicado: (2023)

Prediction of flare following remission and treatment withdrawal in early rheumatoid arthritis: post hoc analysis of a phase IIIb trial with abatacept
por: Ahmad, Harris A., et al.
Publicado: (2022)

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
por: Conaghan, Philip G, et al.
Publicado: (2013)

Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis
por: Mathieu, Sylvain, et al.
Publicado: (2013)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

Seasonal variation in the month of birth in patients with skin cancer
por: La Rosa, F, et al.
Publicado: (2014)

The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapy
por: Backhaus, Tina M, et al.
Publicado: (2013)

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2015)

Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
por: Nüßlein, Hubert G, et al.
Publicado: (2014)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

12-Month naturalistic outcomes of depressive disorders in Hong Kong’s primary care
por: Chin, Weng Yee, et al.
Publicado: (2015)

FATHER–CHILD INTERACTIONS AT 3 MONTHS AND 24 MONTHS: CONTRIBUTIONS TO CHILDREN'S COGNITIVE DEVELOPMENT AT 24 MONTHS
por: Sethna, Vaheshta, et al.
Publicado: (2017)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
por: Simon, T A, et al.
Publicado: (2009)

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
por: Emery, P, et al.
Publicado: (2017)

Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study
por: Jansen, Diahann T S L, et al.
Publicado: (2018)

Baseline serum levels of cross-linked carboxy-terminal telopeptide of type I collagen predict abatacept treatment response in methotrexate-naive, anticitrullinated protein antibody-positive patients with early rheumatoid arthritis
por: Wu, Chun, et al.
Publicado: (2022)

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021)

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab
por: Rubbert-Roth, Andrea, et al.
Publicado: (2022)

Month of birth and risk of autism spectrum disorder: a retrospective cohort of male children born in Israel
por: Shalev, Hila, et al.
Publicado: (2017)

Incidence of laboratory-confirmed influenza disease among infants under 6 months of age: a systematic review
por: Fell, Deshayne B, et al.
Publicado: (2017)

Little in Norway: a prospective longitudinal community-based cohort from pregnancy to child age 18 months
por: Moe, Vibeke, et al.
Publicado: (2019)

Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study
por: Gremese, Elisa, et al.
Publicado: (2013)

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
por: Emery, P, et al.
Publicado: (2009)

Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission
por: Cho, Han Joo, et al.
Publicado: (2022)

Mild COVID-19 despite inadequate antibody response after repeated vaccinations in rheumatic disease patients with rituximab-induced B cell depletion: a case series
por: ten Hagen, Alexander, et al.
Publicado: (2022)

Prevalence and determinants of anaemia in children aged 6–59 months in Africa: a protocol for systematic review and meta-analysis
por: Simo, Larissa Pone, et al.
Publicado: (2020)

Association between birth weight and neurodevelopment at age 1–6 months: results from the Wuhan Healthy Baby Cohort
por: Zhang, Man, et al.
Publicado: (2020)

Real-world predictors of 12–month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study
por: Alten, Rieke, et al.
Publicado: (2017)

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
por: Burmester, Gerd R, et al.
Publicado: (2010)

Response to abatacept is associated with the inhibition of proteasome β1i expression in T cells of patients with rheumatoid arthritis
por: Ghannam, Khetam, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_odi9i0v2fb8q9cu5ljopo620a4